Status:
COMPLETED
A Study to Assess New Participant's Perspectives Beyond Clinical Efficacy of Monoclonal Antibody-Based Relapsing Remitting Multiple Sclerosis (RRMS) Treatments
Lead Sponsor:
Biogen
Conditions:
Multiple Sclerosis, Relapsing-Remitting
Eligibility:
All Genders
18+ years
Brief Summary
The primary objective of the study is to understand what the added value of natalizumab (Tysabri®) treatment is from a participant's perspective at a given time, based on a one-shot survey. The second...
Eligibility Criteria
Inclusion
- • Participants diagnosed with RRMS and followed by a neurologist in France.
Exclusion
- • Lack of literacy
- Note: Other protocol-defined Inclusion/Exclusion criteria may apply.
Key Trial Info
Start Date :
November 24 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 28 2024
Estimated Enrollment :
474 Patients enrolled
Trial Details
Trial ID
NCT06127095
Start Date
November 24 2023
End Date
November 28 2024
Last Update
December 18 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Biogen
Cambridge, Massachusetts, United States, 02142